New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDS5 vs Dulaglutide

DS5 vs Dulaglutide

Side-by-side comparison of key properties, dosing, and research.

Sleep Optimization
DS5
GLP-1 / Weight Loss Agonists
Dulaglutide
Summary
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
Half-Life
Estimated 30-60 minutes (peptide degradation)
~5 days
Admin Route
Subcutaneous, Intranasal (research)
SubQ
Research
Typical Dose
200-500 mcg per dose
0.75 mg → 1.5 mg
Frequency
Once nightly
Once weekly
Key Benefits
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
Side Effects
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
Stacks With